A novel α_Vβ₃ ligand-modified HPMA copolymers for anticancer drug delivery

References

• Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54:675–693.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Singh A, Sihorkar V. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Crit Rev Ther Drug Carrier Syst. 2001;18:1–76.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135–146.
   PubMed Web of Science ®Google Scholar
• Cheresh D. Tumor progression induced by integrin αvβ3 mediated anchorage-dependent and -independent signaling. FASEB J. 2014;28:79–93.
   Google Scholar
• Stenzel D, Wilsch-Bräuninger M, Wong FK, et al. Integrin αvβ3 and thyroid hormones promote expansion of progenitors in embryonic neocortex. Development. 2014;141:795–806.
   PubMed Web of Science ®Google Scholar
• Liu S, Hsieh WY, Jiang Y, et al. Evaluation of a 99mTc-labeled cyclic RGD tetramer for noninvasive imaging integrin αvβ3-positive breast cancer. Bioconjugate Chem. 2007;18:438–446.
   PubMed Web of Science ®Google Scholar
• Guo Z, He B, Jin H, et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering. Biomaterials. 2014;35:6106–6117.
   PubMed Web of Science ®Google Scholar
• Danhier F, Breton AL, Pre´at V. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol Pharmaceutics. 2012;9:2961–2973.
   PubMed Web of Science ®Google Scholar
• Zhan C, Gu B, Xie C, et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release. 2010;143:136–142.
   PubMed Web of Science ®Google Scholar
• Dubey PK, Mishra V, Jain S, et al. Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target. 2004;12:257–264.
   PubMed Web of Science ®Google Scholar
• Pike DB, Ghandehari H. HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv Drug Deliv Rev. 2010;62:167–183.
   PubMed Web of Science ®Google Scholar
• Greish K, Ray A, Bauer H, et al. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release. 2011;151:263–270.
   PubMed Web of Science ®Google Scholar
• Mitra A, Coleman T, Borgman M, et al. Polymeric conjugates of mono-and bi-cyclic α V β 3 binding peptides for tumor targeting. J Control Release. 2006;114:175–183.
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Pola R, Gremse F, et al. Passive versus active tumor targeting using RGD-and NGR-modified polymeric nanomedicines. Nano Lett. 2014;14:972–981.
   PubMed Web of Science ®Google Scholar
• Svensen N, Díaz-Mochón JJ, Bradley M. Decoding a PNA encoded peptide library by PCR: the discovery of new cell surface receptor ligands. Chem Biol. 2011;18:1284–1289.
   PubMed Web of Science ®Google Scholar
• Liu C, Shan W, Liu M, et al. A novel ligand conjugated nanoparticles for oral insulin delivery. Drug Deliv. 2016;23:2015–2025.
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková P, Minko T, et al. HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm. 2000;50:61–81.
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev. 2010;62:122–149.
   PubMed Web of Science ®Google Scholar
• Gianasi E, Wasil M, Evagorou E, et al. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer. 1999;35:994–1002.
   PubMed Web of Science ®Google Scholar
• Lai PS, Lou PJ, Peng CL, et al. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release. 2007;122:39–46.
   PubMed Web of Science ®Google Scholar
• Chytil P, Etrych T, Konak C, et al. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. J Control Release. 2006;115:26–36.
   PubMed Web of Science ®Google Scholar
• Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409–419.
   PubMed Web of Science ®Google Scholar
• Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev. 2010;62:272–282.
   PubMed Web of Science ®Google Scholar
• Allmeroth M, Moderegger D, Biesalski B, et al. Modifying the body distribution of HPMA-based copolymers by molecular weight and aggregate formation. Biomacromolecules. 2011;12:2841–2849.
   PubMed Web of Science ®Google Scholar
• Lammers T, Subr V, Ulbrich K, et al. HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine. 2010;5:1501–1523.
   PubMed Web of Science ®Google Scholar
• Kopeček J, Baẑilová H. Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical polymerization and copolymerization. Eur Polym J. 1973;9:7–14.
   Web of Science ®Google Scholar
• Ulbrich K, Šubr V, Strohalm J, et al. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J Control Release. 2000;64:63–79.
   PubMed Web of Science ®Google Scholar
• Omelyanenko V, Kopečková P, Gentry C, et al. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release. 1998;53:25–37.
   PubMed Web of Science ®Google Scholar
• Etrych T, Mrkvan T, Chytil P, et al. N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation. J Appl Polym Sci. 2008;109:3050–3061.
   Web of Science ®Google Scholar
• Li L, Yang Q, Zhou Z, et al. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting. Biomaterials. 2014;35:5171–5187.
   PubMed Web of Science ®Google Scholar
• Li L, Sun W, Zhong J, et al. Multistage nanovehicle delivery system based on stepwise size reduction and charge reversal for programmed nuclear targeting of systemically administered anticancer drugs. Adv Funct Mater. 2015;25:4101–4113.
   Web of Science ®Google Scholar
• Xu X, Li L, Zhou Z, et al. Dual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin. Int J Pharm. 2016;507:50–60.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Xu X, Li L, et al. Improvement of anti-tumor abilities on human non-small cell lung carcinoma by micellization and cross-linking of N-(2-hydroxypropyl) methacrylamide copolymers. J Drug Target. 2015;23:821–831.
   PubMed Web of Science ®Google Scholar
• Sun W, Li L, Yang Q, et al. G3-C12 peptide reverses galectin-3 from foe to friend for active targeting cancer treatment. Mol Pharm. 2015;12:4124–4136.
   PubMed Web of Science ®Google Scholar
• Mitra A, Nan A, Papadimitriou JC, et al. Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol. 2006;33:43–52.
   PubMed Web of Science ®Google Scholar
• Luo Y, Bernshaw NJ, Lu ZR, et al. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res. 2002;19:396–402.
   PubMed Web of Science ®Google Scholar
• Zhang R, Luo K, Yang J, et al. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. J Control Release. 2013;166:66–74.
   PubMed Web of Science ®Google Scholar
• Vercauteren D, Piest M, van der Aa LJ, et al. Flotillin-dependent endocytosis and a phagocytosis-like mechanism for cellular internalization of disulfide-based poly(amido amine)/DNA polyplexes. Biomaterials. 2011;32:3072–3084.
   PubMed Web of Science ®Google Scholar
• Rayapureddi JP, Tomamichel WJ, Walton ST, et al. TAT fusion protein transduction into isolated mitochondria is accelerated by sodium channel inhibitors. Biochemistry. 2010;49:9470–9479.
   PubMed Web of Science ®Google Scholar
• Xiang S, Zhang X. Cellular uptake mechanism of non-viral gene delivery and means for improving transfection efficiency. In: Martin F, editor. Gene therapy – Tools and potential applications. Vol. 4. InTech; 2013. p. 71–90.
   Google Scholar
• Xiao J, Duan X, Yin Q, et al. Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer. Biomaterials. 2013;34:9648–9656.
   PubMed Web of Science ®Google Scholar
• Rihova B, Hovorka O, Kovar L, et al. HPMA-anticancer drug conjugates. Macromolecular Anticancer Therapeutics. New York: Springer; 2010. p. 87–132.
   Google Scholar
• Ruan S, Yuan M, Zhang L, et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials. 2015;37:425–435.
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991–1003.
   PubMed Web of Science ®Google Scholar
• Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today. 2002;7:569–579.
   PubMed Web of Science ®Google Scholar
• Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochm Soc Trans. 2007;35:56–60.
   PubMed Web of Science ®Google Scholar
• Capasso D, de Paola I, Liguoro A, et al. RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells. PLoS One. 2014;9:e106441.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang W, Samarsky D, et al. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucl Acids Res. 2014:42:11805–11817.
   PubMed Web of Science ®Google Scholar
• Borgne-Sanchez A, Dupont S, Langonne A, et al. Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of αvβ3-expressing endothelial cells. Cell Death Differ. 2007;14:422–435.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang T, Wang X, et al. Targeted polymeric micelle system for delivery of combretastatin A4 to tumor vasculature in vitro. Pharm Res. 2010;27:1861–1868.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
   PubMed Web of Science ®Google Scholar
• Stafman LL, Beierle AE. Cell proliferation in neuroblastoma. Cancer. 2016;8:13.
   Google Scholar
• Lisanti MP, Schook W, Moskowitz N, et al. Brain clathrin: studies of its ultrastructural assemblies. Eur J Biochem. 1982;121:617–622.
   PubMedGoogle Scholar
• Barbuti A, Scavone A, Mazzocchi N, et al. A caveolin-binding domain in the HCN4 channels mediates functional interaction with caveolin proteins. J Mol Cell Cardiol. 2012;53:187–195.
   PubMed Web of Science ®Google Scholar
• Schnitzer JE, Oh P, Pinney E, et al. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J Cell Biol. 1994;127:1217.
   PubMed Web of Science ®Google Scholar